Chairperson(s) : Young Joon Hong (Chonnam National University, Republic of Korea), Weon Kim (Kyung Hee University, Republic of Korea)
Panel(s) : Ung Kim (Yeungnam University, Republic of Korea), Chang-Hoon Woo (Yeungnam University, Republic of Korea), Jong-Chan Youn (The Catholic University of Korea, Republic of Korea)
-
LDL versus inflammation: what remains after aggressive lipid lowering?
Osung Kwon The Catholic University of Korea, Republic of Korea 13:00~13:18 -
Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond
Sung-A Bae Yonsei University, Republic of Korea 13:18~13:36 -
Colchicine for secondary prevention in ASCVD
Dae Young Cheon Hallym University, Republic of Korea 13:36~13:54 -
Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets
Christoph J. Binder Medical University of Vienna, Austria 13:54~14:12 - Panel Discussion 14:12~14:30
Chairperson(s) : Eun Gyoung Hong (Hallym University, Republic of Korea), Chul Sik Kim (Yonsei University, Republic of Korea)
Panel(s) : Shinae Kang (Yonsei University, Republic of Korea), JiHyun Ahn (Korea Medical Institute, Republic of Korea), Jung-Joon Cha (Korea University, Republic of Korea)
-
Sex differences in lymphatic function and atherosclerosis outcomes
Catherine Martel University of Montreal, Canada 16:10~16:30 -
Tirzepatide and cardiometabolic outcomes: implications of dual GLP-1/GIP agonism
Yun Kyung Cho University of Ulsan, Republic of Korea 16:30~16:50 -
Effects of SGLT2 inhibitors on lipid metabolism: mechanisms and clinical implications
Jun Hwa Hong Eulji University, Republic of Korea 16:50~17:10 - Panel Discussion 17:10~17:40
